With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

GLP-1 drugs like (Ozempic and Wegovy) have finally started to make weight loss a sustainable reality for many people with ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

A science-based weight loss protocol designed to help men lose fat, preserve muscle, and improve metabolic health ...

A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping ...

Alternatives to Ozempic for Weight Loss This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic is an ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this strategy may not be effective for everyone.

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.